MiMedx Group, Inc (MDXG) to Release Quarterly Earnings on Wednesday

MiMedx Group, Inc (NASDAQ:MDXG) will announce its earnings results before the market opens on Wednesday, October 25th. Analysts expect the company to announce earnings of $0.08 per share for the quarter. MiMedx Group has set its FY17 guidance at $0.31-0.33 EPS.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, July 26th. The medical equipment provider reported $0.07 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.07. MiMedx Group had a net margin of 7.48% and a return on equity of 15.95%. The business had revenue of $76.40 million for the quarter, compared to analyst estimates of $74.22 million. During the same period in the prior year, the business posted $0.05 earnings per share. MiMedx Group’s revenue was up 33.3% compared to the same quarter last year. On average, analysts expect MiMedx Group to post $0.25 EPS for the current fiscal year and $0.44 EPS for the next fiscal year.

MiMedx Group, Inc (NASDAQ MDXG) opened at 13.82 on Wednesday. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 72.74 and a beta of 0.91. The company has a 50-day moving average of $13.56 and a 200 day moving average of $13.90. MiMedx Group, Inc has a one year low of $7.64 and a one year high of $17.47.

MiMedx Group announced that its Board of Directors has approved a share buyback plan on Wednesday, July 26th that allows the company to buyback $14.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 0.9% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://ledgergazette.com/2017/10/18/mimedx-group-inc-mdxg-to-release-quarterly-earnings-on-wednesday.html.

A number of analysts have recently commented on the stock. Needham & Company LLC boosted their target price on shares of MiMedx Group from $20.00 to $21.00 and gave the company a “strong-buy” rating in a report on Tuesday, September 5th. Piper Jaffray Companies restated a “buy” rating and set a $18.00 target price on shares of MiMedx Group in a report on Sunday, August 20th. BidaskClub upgraded shares of MiMedx Group from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Lake Street Capital boosted their target price on shares of MiMedx Group from $16.00 to $18.00 and gave the company a “buy” rating in a report on Friday, July 28th. Finally, Zacks Investment Research cut shares of MiMedx Group from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $14.83.

MiMedx Group Company Profile

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomateria

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, July 26th. The medical equipment provider reported $0.07 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.07. MiMedx Group had a net margin of 7.48% and a return on equity of 15.95%. The business had revenue of $76.40 million for the quarter, compared to analyst estimates of $74.22 million. During the same period in the prior year, the business posted $0.05 earnings per share. MiMedx Group’s revenue was up 33.3% compared to the same quarter last year. On average, analysts expect MiMedx Group to post $0.25 EPS for the current fiscal year and $0.44 EPS for the next fiscal year.

MiMedx Group, Inc (NASDAQ MDXG) opened at 13.82 on Wednesday. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 72.74 and a beta of 0.91. The company has a 50-day moving average of $13.56 and a 200 day moving average of $13.90. MiMedx Group, Inc has a one year low of $7.64 and a one year high of $17.47.

MiMedx Group announced that its Board of Directors has approved a share buyback plan on Wednesday, July 26th that allows the company to buyback $14.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 0.9% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://ledgergazette.com/2017/10/18/mimedx-group-inc-mdxg-to-release-quarterly-earnings-on-wednesday.html.

A number of analysts have recently commented on the stock. Needham & Company LLC boosted their target price on shares of MiMedx Group from $20.00 to $21.00 and gave the company a “strong-buy” rating in a report on Tuesday, September 5th. Piper Jaffray Companies restated a “buy” rating and set a $18.00 target price on shares of MiMedx Group in a report on Sunday, August 20th. BidaskClub upgraded shares of MiMedx Group from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Lake Street Capital boosted their target price on shares of MiMedx Group from $16.00 to $18.00 and gave the company a “buy” rating in a report on Friday, July 28th. Finally, Zacks Investment Research cut shares of MiMedx Group from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $14.83.

MiMedx Group Company Profile

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.

Earnings History for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply